Condition: Adults With Overweight/Obesity and Type 2 Diabetes · Sponsor: Antag Therapeutics
The goal of this clinical trial is to learn if AT673 contributes to additional weight loss and glycemic control when given with semaglutide in participants with overweight/obesity and type 2 diabetes. The main questions it aims to answer are: * To compare the effect on body weight of two doses of AT673 once-weekly versus matched placebo when concurrently administered with semaglutide once-weekly * To evaluate the effect of AT673 on glycated hemoglobin (HbA1c) * To compare the safety and tolerability of AT673 versus matched placebo when concurrently administered with semaglutide
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| CenExel Phoenix | Chandler, Arizona, United States | Recruiting |
| CenExel Anaheim | Anaheim, California, United States | Recruiting |
| CenExel Hollywood | Hollywood, Florida, United States | Recruiting |
| CenExel Tampa | Tampa, Florida, United States | Recruiting |
| CenExel Atlanta | Atlanta, Georgia, United States | Recruiting |
| CenExel Decatur | Decatur, Georgia, United States | Recruiting |
| CenExel Savannah | Savannah, Georgia, United States | Recruiting |
| CenExel SLC | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07724340